(S)-2-(4-chlorophenyl)-N-(5-fluorothiazol-2-yl)-3-methylbutanamide | 1103523-25-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (S)-2-(4-chlorophenyl)-N-(5-fluorothiazol-2-yl)-3-methylbutanamide
• 英文别名: (S)-4-Cmtb；(2S)-2-(4-chlorophenyl)-N-(5-fluoro-1,3-thiazol-2-yl)-3-methylbutanamide
• CAS: 1103523-25-6
• 化学式: C₁₄H₁₄ClFN₂OS
• 分子量: 312.795
• InChiKey: VMELOMANPNYLFR-LBPRGKRZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  20
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  70.2
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  5-氟-2-氨基噻唑 、 (S)-2-(4-氯苯基)-3-甲基丁酸 在 2,4,6-三甲基吡啶 、 草酰氯 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 生成 (S)-2-(4-chlorophenyl)-N-(5-fluorothiazol-2-yl)-3-methylbutanamide
  参考文献：
  名称：

  The first synthetic agonists of FFA2: Discovery and SAR of phenylacetamides as allosteric modulators

  摘要：

  Free fatty acid receptor 2 (FFA2) is a G-protein coupled receptor for which only short-chain fatty acids (SCFAs) have been reported as endogenous ligands. We describe the discovery and optimization of phenylacetamides as allosteric agonists of FFA2. These novel ligands can suppress adipocyte lipolysis in vitro and reduce plasma FFA levels in vivo, suggesting that these allosteric modulators can serve as pharmacological tools for exploring the potential function of FFA2 in various disease conditions. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.11.112

文献信息

• Compositions containing combinations of bioactive molecules derived from microbiota for treatment of disease
  申请人：Vedanta Biosciences, Inc.

  公开号：US10130695B2

  公开（公告）日：2018-11-20

  Compositions consisting of bioactive molecules derived from the microbiota of a mammal are provided herein. When administered orally with a colonic delivery system, the compositions are useful for the prophylaxis and treatment of diseases, in particular inflammatory, autoimmune and infectious diseases. The compositions comprise combinations of small molecules and bacterial antigens formulated in colonic delivery systems. Use of the compositions results in any or all of: induction of immune tolerance; strengthening of the gut mucosal barrier integrity; reduction of inflammation; and amelioration of a disease state caused by inflammation, an autoimmune reaction or an infectious agent.

  本文提供了由源自哺乳动物微生物群的生物活性分子组成的组合物。当通过结肠给药系统口服给药时，这些组合物可用于预防和治疗疾病，特别是炎症、自身免疫性和传染性疾病。这些组合物由小分子和细菌抗原组合而成，配制在结肠给药系统中。使用这些组合物可以达到以下任何或全部效果：诱导免疫耐受；增强肠道粘膜屏障的完整性；减少炎症；改善由炎症、自身免疫反应或感染性病原体引起的疾病状态。
• COMPOSITIONS CONTAINING COMBINATIONS OF BIOACTIVE MOLECULES DERIVED FROM MICROBIOTA FOR TREATMENT OF DISEASE
  申请人：Puretech Ventures, LLC

  公开号：EP3019181A2

  公开（公告）日：2016-05-18
• US9764019B2
  申请人：——

  公开号：US9764019B2

  公开（公告）日：2017-09-19
• [EN] COMPOSITIONS CONTAINING COMBINATIONS OF BIOACTIVE MOLECULES DERIVED FROM MICROBIOTA FOR TREATMENT OF DISEASE<br/>[FR] COMPOSITIONS CONTENANT DES COMBINAISONS DE MOLÉCULES BIOACTIVES DÉRIVÉES D'UNE MICROFLORE POUR LE TRAITEMENT D'UNE MALADIE
  申请人：PURETECH VENTURES LLC

  公开号：WO2015006355A2

  公开（公告）日：2015-01-15

  Compositions consisting of bioactive molecules derived from the microbiota of a mammal are provided herein. When administered orally with a colonic delivery system, the compositions are useful for the prophylaxis and treatment of diseases, in particular inflammatory, autoimmune and infectious diseases. The compositions comprise combinations of small molecules and bacterial antigens formulated in colonic delivery systems. Use of the compositions results in any or all of: induction of immune tolerance; strengthening of the gut mucosal barrier integrity; reduction of inflammation; and amelioration of a disease state caused by inflammation, an autoimmune reaction or an infectious agent.
• [EN] ALLERGY TREATMENT<br/>[FR] TRAITEMENT ANTI-ALLERGIQUE
  申请人：PROTA THERAPEUTICS PTY LTD

  公开号：WO2021127736A1

  公开（公告）日：2021-07-01

  The present invention concerns a method of treating peanut allergy in a subject, or a population of subjects, the method comprising administering to said subject or population of subjects a peanut allergen by an oral immunotherapy (OIT) regimen comprising a dose escalation phase in which the peanut allergen is administered in a dose which is increased in increments from an initial dose of the allergen equivalent of 5 mg peanut protein or less to a dose of the allergen equivalent of 200 mg peanut protein or more within 4 to 9 weeks from the administration of the initial dose. The treatment reduces the length of the build-up phase in peanut OIT methods and improves the likelihood or odds of the subject achieving sustained unresponsiveness.